Does Blue Cross Blue Shield of Illinois Cover Lantus?

How Formularies Work and Where Lantus Fits

Most BCBSIL commercial plans use a 5-tier formulary. Generic drugs sit on Tier 1, preferred generics on Tier 2, preferred brand-name drugs on Tier 3, non-preferred brands on Tier 4, and specialty drugs on Tier 5. Lantus is a brand-name insulin with multiple FDA-approved biosimilar competitors. That competition has caused many insurers, including BCBSIL, to move Lantus off the preferred-brand tier and onto the non-preferred tier in plan years 2023 through 2025.

What "Non-Preferred Brand" Means for Your Wallet

A Tier 4 placement typically means a higher fixed copay (often $60 to $90 per 30-day supply on commercial plans) or a coinsurance percentage of 40% to 50% of the plan's allowable cost after your deductible is met. Before your deductible is satisfied, you may pay the full contracted rate, which for a package of five Lantus SoloSTAR pens (1,500 units total) can reach $250 to $450 depending on the plan's negotiated rate.

Preferred Alternatives on Many BCBSIL Formularies

BCBSIL plan sponsors have increasingly placed Basaglar KwikPen (insulin glargine, Eli Lilly) and Semglee (insulin glargine-yfgn, Biocon/Viatris) on Tier 3 as preferred brand alternatives. The FDA approved Semglee as biosimilar and interchangeable with Lantus in July 2021 (1), allowing pharmacists in Illinois to automatically substitute Semglee at the pharmacy counter without contacting the prescriber. Clinically, Semglee delivers the same 24-hour basal insulin profile and the same dosing schedule as Lantus.

How to Look Up Your Specific Plan's Lantus Tier

1. Log in to your account at bcbsil.com and manage to "Drug Cost Estimator."
2. Enter "insulin glargine" or "Lantus" in the search bar.
3. Select your pharmacy (retail vs. Mail-order; mail-order is usually cheaper for maintenance medications).
4. The tool will return your current tier, copay or coinsurance, and any coverage restrictions.

Calling the Member Services phone number printed on the back of your insurance card is equally reliable. Ask the representative specifically: "Is Lantus on my formulary, and is prior authorization required?"

Prior Authorization Requirements for Lantus

Prior authorization (PA) is a written approval process in which your prescriber submits clinical evidence to BCBSIL before the plan pays for the medication. BCBSIL requires PA for Lantus on many commercial plan designs, particularly when a preferred biosimilar is listed on the same formulary.

Typical PA Criteria BCBSIL Uses

PA criteria are not published publicly in a single document, but BCBSIL generally follows criteria consistent with the American Diabetes Association (ADA) Standards of Care. According to the ADA's 2024 Standards of Medical Care in Diabetes: "Insulin therapy is recommended for patients with type 1 diabetes and for patients with type 2 diabetes who do not achieve glycemic targets with other agents." (2)

Common documentation that supports a PA approval includes:

• A confirmed diagnosis of type 1 or type 2 diabetes with an HbA1c reading above 7.0% (or above 8.0% for certain plan designs).
• Documentation of a clinical reason why Basaglar or Semglee are not appropriate (e.g., pen device incompatibility for a patient with dexterity limitations, documented adverse reaction, or prescriber attestation of clinical necessity).
• Prior 30-to-90-day trial of a preferred biosimilar, depending on the plan's step-therapy requirements.

Step Therapy and How to Bypass It

Step therapy means you must try a preferred drug for a defined period before the plan approves the non-preferred drug. Illinois passed the Step Therapy Reform Act (820 ILCS 191), which requires insurers to grant step-therapy overrides when the preferred medication is contraindicated, when the patient previously tried and failed the preferred medication, or when step therapy would cause the patient serious adverse effects. If your prescriber believes Lantus is medically necessary and biosimilar substitution poses a clinical risk, they can submit an override request citing the Illinois Step Therapy Reform Act.

Average PA Decision Timeline

BCBSIL is required under Illinois law to respond to a standard PA request within 2 business days and to an urgent/expedited request within 24 hours. If denied, you have the right to an internal appeal and then an external independent review.

Medicare and Medicaid: Different Rules Apply

If you are covered by a BCBSIL Medicare Advantage or Medicare Part D plan rather than a commercial plan, the rules differ in two important ways.

Medicare Part D Coverage for Lantus

All Medicare Part D formularies must include at least two insulins in each therapeutic class. Lantus or a biosimilar equivalent appears on virtually all Part D formularies. The Inflation Reduction Act of 2022 capped cost-sharing for covered insulin at $35 per month per insulin product starting January 1, 2023, for Medicare beneficiaries. (3) This $35 cap applies at every phase of the Part D benefit, including the deductible phase.

Illinois Medicaid (Medicaid Managed Care)

BCBSIL administers Medicaid Managed Care plans in Illinois (Meridian by BCBSIL). Lantus is listed on the Illinois Medicaid preferred drug list with a quantity limit of one vial or one package of five SoloSTAR pens per 30 days. Medicaid members typically pay $0 to $4 for covered formulary drugs in Illinois, making cost a lesser concern than on commercial plans.

Biosimilar Alternatives to Lantus Covered by BCBSIL

Three FDA-approved insulin glargine biosimilars are relevant to BCBSIL coverage decisions as of 2025.

Basaglar (insulin glargine, Eli Lilly)

Basaglar was the first insulin glargine follow-on product approved in the United States (December 2015). It is not designated as interchangeable with Lantus, meaning automatic pharmacist substitution is not permitted. Your prescriber must write a new prescription for Basaglar specifically, or endorse a change. BCBSIL commercial plans commonly place Basaglar on Tier 3 with a $40 to $60 copay per 30-day supply.

A 2018 randomized non-inferiority trial published in Diabetes Care (N=536) demonstrated that Basaglar produced HbA1c reductions and hypoglycemia rates equivalent to Lantus over 24 weeks in patients with type 2 diabetes. (4)

Semglee (insulin glargine-yfgn, Biocon/Viatris)

The FDA's July 2021 approval of Semglee as the first interchangeable biosimilar insulin in the United States is a meaningful regulatory milestone. (1) Interchangeability means that a pharmacist in Illinois can substitute Semglee for a Lantus prescription without prior prescriber authorization (though the pharmacist must notify the prescriber in most circumstances). The list price of Semglee is approximately 65% lower than Lantus. BCBSIL plans commonly list Semglee on Tier 2 or Tier 3 with copays as low as $25 per 30-day supply.

Rezvoglar (insulin glargine-aglr, Eli Lilly)

Eli Lilly launched Rezvoglar in January 2023 at a list price of $92 per package of five KwikPens, roughly 78% below the Lantus list price. The FDA approved Rezvoglar as interchangeable with Lantus. Some BCBSIL plan designs added Rezvoglar to the formulary in 2024 benefit years. Check your specific formulary to see if it is listed.

What Lantus Actually Costs Without Good Coverage

Understanding the uninsured or high-deductible cost helps you negotiate and compare. At retail pharmacies in Illinois, a package of five Lantus SoloSTAR pens (3 mL each, 100 units/mL) carries a list price near $530. Through discount platforms such as GoodRx, the cash price ranges from $175 to $280 depending on the pharmacy. The Sanofi Insulins Valyou Savings Program allows eligible commercially insured or uninsured patients to purchase Lantus for $99 per month (up to 10 boxes of pens or 10 vials). (5)

The cost comparison framework below summarizes your realistic monthly out-of-pocket under each coverage scenario for a patient requiring 30 units of basal insulin per day (approximately one SoloSTAR pen package per month):

| Coverage Scenario | Typical Monthly Cost (2025 Estimate) | |---|---| | BCBSIL commercial, Lantus Tier 4, deductible met | $60 to $90 copay | | BCBSIL commercial, Lantus Tier 4, deductible not met | $175 to $280 (plan contracted rate) | | BCBSIL commercial, Semglee Tier 3, deductible met | $25 to $50 copay | | BCBSIL Medicare Part D | $35 cap (Inflation Reduction Act) | | Illinois Medicaid (Meridian BCBSIL) | $0 to $4 | | No insurance, Sanofi Valyou program | $99 | | No insurance, GoodRx cash price (Semglee) | $55 to $85 |

The Clinical Case for Sticking With Lantus vs. Switching

Some patients and prescribers are concerned about switching from Lantus to a biosimilar. The clinical evidence supports biosimilar equivalence, but there are legitimate reasons a prescriber might document clinical necessity for Lantus specifically.

Glycemic Equivalence Data

A 2020 systematic review and meta-analysis published in Diabetes, Obesity and Metabolism (pooled N=2,814 across 7 randomized controlled trials) found no statistically significant difference in HbA1c reduction, fasting plasma glucose, or rates of severe hypoglycemia between insulin glargine biosimilars and Lantus U-100. (6) The mean HbA1c difference across trials was 0.04% (95% CI: -0.08 to 0.16%), well within the non-inferiority margin of 0.4% used by the FDA.

Legitimate Reasons to Preserve a Lantus Prescription

Device compatibility matters in practice. Lantus SoloSTAR pens use specific pen needles and have a particular injection mechanism. Patients with severe rheumatoid arthritis or limited hand strength may be stabilized on a specific device. A prescriber can document this in a PA or step-therapy override. Formulary exceptions are routinely granted when device-specific medical necessity is well-documented.

What the ADA Says

The ADA's 2024 Standards of Medical Care state: "When a less costly alternative is available and is clinically appropriate, cost considerations should guide insulin selection, as adherence is strongly influenced by affordability." (2) This guidance supports switching to a biosimilar when cost is a barrier to adherence.

How to Get Lantus Covered by BCBS Illinois: Step-by-Step

Getting Lantus approved when your plan initially denies it or places it at a high tier takes persistence but follows a clear process.

Step 1: Confirm Your Plan's Current Formulary Status

Do not rely on last year's formulary. BCBSIL updates formularies on January 1 of each plan year. Log in to bcbsil.com or call Member Services to confirm the current tier and any PA requirements for Lantus under your specific group plan or individual plan ID.

Step 2: Ask Your Prescriber to Submit a Prior Authorization

Your endocrinologist, primary care physician, or certified diabetes care and education specialist (CDCES) initiates the PA by completing BCBSIL's PA request form. They document your diagnosis, current HbA1c, history of hypoglycemia, any contraindications to biosimilar alternatives, and medical necessity for the branded product.

Step 3: Invoke Step-Therapy Override Rights if Applicable

If BCBSIL denies coverage under step therapy, ask your prescriber to submit a step-therapy exception citing the Illinois Step Therapy Reform Act (820 ILCS 191). The law requires insurers to grant exceptions when the preferred medication is clinically inappropriate for the specific patient. (7)

Step 4: File an Internal Appeal

If the PA is denied, you have 180 days from the denial date to file an internal appeal with BCBSIL. Submit supporting clinical notes, HbA1c lab results, and a letter of medical necessity from your prescriber. BCBSIL must respond to a standard appeal within 30 days and an expedited appeal within 72 hours under Illinois insurance regulations.

Step 5: Request External Independent Review

If the internal appeal is denied, Illinois law gives you the right to an external independent review conducted by an organization certified by the Illinois Department of Insurance. External reviewers overturn insurer denials at rates ranging from 30% to 45% depending on the drug class, according to data published by the Kaiser Family Foundation. (8)

Step 6: Use Manufacturer Savings While the Appeal Proceeds

While your appeal is pending, activate the Sanofi Valyou Savings Program to cap your cost at $99/month. You can switch back to insurance billing once coverage is approved. The savings program is available at Valyou.insulinsofamerica.com and does not require income documentation for the standard $99 tier.

Special Populations: Type 1 Diabetes, Pregnancy, and Pediatric Patients

Coverage criteria sometimes differ by indication, and knowing this can strengthen a PA request.

Type 1 Diabetes

Patients with type 1 diabetes have no functioning beta cells. Basal insulin is not optional; it is survival therapy. BCBSIL PA reviewers are significantly less likely to deny Lantus for type 1 diabetes than for type 2, because step therapy into an oral agent is not medically possible, and biosimilar substitution without the patient's knowledge carries greater clinical risk in this population. The ADA and the American Association of Clinical Endocrinology (AACE) both emphasize that disrupting a stable insulin regimen in type 1 diabetes carries meaningful hypoglycemia risk. (9)

Pregnancy and Gestational Diabetes

The FDA classifies insulin glargine as Pregnancy Category C. The preferred basal insulin in pregnancy per ACOG Practice Bulletin No. 201 is NPH insulin (human insulin isophane), because long-term safety data in pregnancy are more extensive. (10) Some BCBSIL plans actually require step therapy toward NPH during pregnancy rather than approving Lantus. Discuss this with your maternal-fetal medicine specialist or endocrinologist early in the pregnancy.

Pediatric Patients (Age <18)

The FDA approved Lantus for use in pediatric patients with type 1 diabetes aged 6 years and older. BCBSIL pediatric formularies generally mirror the adult formulary tier structure, but some pediatric-specific group plans (through employer or CHIP) place all insulins on Tier 2 with lower copays. Parents of children with type 1 diabetes should ask whether the child's plan qualifies for CHIP in Illinois if household income falls below 142% of the federal poverty level.

Mail-Order Pharmacy and Specialty Pharmacy Options

BCBSIL partners with its own specialty pharmacy (Prime Therapeutics) and with major mail-order pharmacies. Ordering a 90-day supply through mail order typically reduces the per-unit cost. On many BCBSIL plans, a 90-day mail-order supply of a Tier 3 insulin costs the equivalent of two retail 30-day copays rather than three, saving one copay per quarter. If Lantus is on Tier 4, the 90-day mail-order cost may still be lower than three retail fills if the plan applies a quantity discount to mail-order pricing.

Ask your BCBSIL Member Services representative: "What is the mail-order cost for a 90-day supply of Lantus vs. Semglee, and does the mail-order pharmacy allow interchangeable biosimilar substitution?"

Monitoring Glycemic Control After Any Insulin Change

Switching from Lantus to a biosimilar or changing formulary coverage mid-year should trigger a brief monitoring period. The endocrine community generally recommends checking fasting blood glucose daily for the first 2 weeks after any basal insulin change, with a follow-up HbA1c at 3 months. The American Association of Clinical Endocrinology's 2022 Diabetes Algorithm recommends maintaining fasting glucose targets of 80 to 130 mg/dL for most non-pregnant adults with type 2 diabetes. (9) If fasting glucose rises above 180 mg/dL on two consecutive mornings after a formulary-driven switch, contact your prescriber for a dose titration consultation before making independent dose adjustments.